Slow Capital Inc. reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 32.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,075 shares of the biopharmaceutical company’s stock after selling 5,244 shares during the period. Slow Capital Inc.’s holdings in Nektar Therapeutics were worth $394,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. First Trust Advisors LP boosted its holdings in shares of Nektar Therapeutics by 39.9% in the 2nd quarter. First Trust Advisors LP now owns 3,005,999 shares of the biopharmaceutical company’s stock valued at $106,953,000 after buying an additional 856,819 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in shares of Nektar Therapeutics by 4.1% in the 1st quarter. Frontier Capital Management Co. LLC now owns 828,350 shares of the biopharmaceutical company’s stock valued at $27,833,000 after buying an additional 32,961 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Nektar Therapeutics by 3.3% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 704,940 shares of the biopharmaceutical company’s stock valued at $25,082,000 after buying an additional 22,563 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of Nektar Therapeutics by 3.3% in the 1st quarter. Rice Hall James & Associates LLC now owns 670,359 shares of the biopharmaceutical company’s stock valued at $22,524,000 after buying an additional 21,357 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Nektar Therapeutics by 2.9% in the 1st quarter. Swiss National Bank now owns 577,500 shares of the biopharmaceutical company’s stock valued at $19,404,000 after buying an additional 16,500 shares in the last quarter. Institutional investors and hedge funds own 92.48% of the company’s stock.

In other Nektar Therapeutics news, CFO Gil M. Labrucherie sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $34.57, for a total transaction of $864,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Howard W. Robin sold 33,334 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $32.11, for a total transaction of $1,070,354.74. Following the transaction, the chief executive officer now directly owns 328,659 shares of the company’s stock, valued at $10,553,240.49. The disclosure for this sale can be found here. Insiders have sold a total of 253,283 shares of company stock valued at $8,356,254 over the last three months. 4.02% of the stock is currently owned by insiders.

Shares of Nektar Therapeutics stock traded down $0.43 during midday trading on Wednesday, hitting $18.15. The company had a trading volume of 1,730,547 shares, compared to its average volume of 1,872,587. The stock has a market capitalization of $3.29 billion, a PE ratio of 4.80 and a beta of 2.67. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The business has a fifty day moving average price of $31.37. Nektar Therapeutics has a 12-month low of $17.50 and a 12-month high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.17. The firm had revenue of $23.32 million during the quarter, compared to analyst estimates of $26.65 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 24.67%. Nektar Therapeutics’s revenue was down 97.9% on a year-over-year basis. During the same period last year, the firm posted $5.33 EPS. As a group, sell-side analysts anticipate that Nektar Therapeutics will post -3.13 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on NKTR. ValuEngine upgraded shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Cowen set a $82.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 13th. TheStreet lowered shares of Nektar Therapeutics from a “c” rating to a “d” rating in a research report on Thursday, August 8th. William Blair reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Friday, August 9th. Finally, BidaskClub lowered shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $49.15.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Read More: Net Income

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.